No Data
No Data
Incyte Zynyz Improves Progression-free Survival in Anal Cancer
Unusual Options Activity: F, INCY and Others Attract Market Bets, F V/OI Ratio Reaches 416.7
BofA Securities Maintains Incyte(INCY.US) With Hold Rating, Raises Target Price to $66
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Cantor Fitzgerald Reiterates Neutral on Incyte
Incyte Analyst Ratings
No Data
No Data